Drug Profile
ABI 1968
Alternative Names: ABI1968; HTI-1968Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Hera Therapeutics
- Developer Antiva Biosciences
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Apoptosis stimulants; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anal intraepithelial neoplasia; Cervical intraepithelial neoplasia; Herpesvirus infections; HIV infections; Human papillomavirus infections; Vulvar intraepithelial neoplasia
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Cervical-intraepithelial-neoplasia in South Africa (Topical, Cream)
- 28 Feb 2021 No recent reports of development identified for phase-I development in Cervical-intraepithelial-neoplasia in USA (Topical, Cream)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Vulvar-intraepithelial-neoplasia in USA (Topical)